title: Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review.
abstract: Emerging evidence supports the concept that biochemical markers are clinically useful non-invasive diagnostic tools for the monitoring of changes in cartilage turnover in patients with destructive joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). Epidemiological studies demonstrated that measurements of different degradation products of proteins in the extracellular matrix of hyaline cartilage in urine or serum samples are (1) increased in OA or RA patients compared with healthy individuals, (2) correlate with disease activity, and (3) are predictive for the rate of changes in radiographic measures of cartilage loss. The present review provides an updated list of available biomarkers and summarize the research data arguing for their clinical utility. In addition, it addresses the question whether or not the monitoring of biomarkers during different treatment modalities could be a useful approach to characterize the chondro-protective effects of approved and candidate drugs. Finally, it briefly reviews the in vitro/ex vivo experimental settings - isolated chondrocyte cultures and articular cartilage explants - that can assist in the verification of novel markers, but also studies assessing direct effects of drug candidates on chondrocytes. Collectively, biomarkers may acquire a function as established efficacy parameters in the clinical development of novel chondro-protective agents.
authors.affiliation: Nordic Bioscience A/S, Herlev, Denmark. eus@nordicbioscience.com
authors.forename: E U
authors.initials: EU
authors.lastname: Sumer
authors.forename: S
authors.initials: S
authors.lastname: Schaller
authors.forename: B C
authors.initials: BC
authors.lastname: Sondergaard
authors.forename: L B
authors.initials: LB
authors.lastname: Tankó
authors.forename: P
authors.initials: P
authors.lastname: Qvist
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology; D015415:Biomarkers / Q000032:analysis*; D002356:Cartilage / Q000187:drug effects / Q000378:metabolism*; D015195:Drug Design; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy* / Q000473:pathology; D010003:Osteoarthritis / Q000188:drug therapy; D020011:Protective Agents / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D020011:Protective Agents